Heron Therapeutics stock faces a guidance reset after Q2 loss

Published on 10/07/2026 at 07:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Heron Therapeutics stock was trading at USD 0.34 on October 6, 2026, while Q2 sales reached USD 37.7 million. Analysts retain a Hold consensus.

HRTX, US4277461020, Illustration mit AI erstellt.

Heron Therapeutics (ISIN US4277461020) was trading at USD 0.34 on Nasdaq on October 6, 2026, giving the company a market capitalization of USD 63.9 million. The Q2 2026 report showed revenue below consensus and a withdrawn full-year outlook, while a new licensing agreement adds a strategic development angle.

Q2 sales missed expectations

According to MetaTrader, Heron reported USD 37.7 million in net product sales for the quarter ended June 30, 2026, compared with USD 37.2 million in Q2 2025. The company posted a net loss of USD 5.5 million, or USD 0.03 per diluted share, versus a USD 2.4 million loss in the comparable quarter.

The sales figure also trailed the USD 42.19 million analyst estimate cited by MarketBeat. Gross margin was 69.3 percent in Q2 2026, down from 73.5 percent a year earlier, adding pressure to a business already managing a net loss.

License deal broadens the pipeline

Heron entered a multi-product development and license agreement with Long Grove Pharmaceuticals and Capstone Development Services effective September 23, 2026, according to Investing.com. The arrangement grants Heron exclusive rights to import, distribute, sell and market certain products in the United States, with milestone payments and royalties tied to the agreement.

The strategic value sits beside a difficult near-term operating picture. The Q2 filing summary states that Heron withdrew its 2026 guidance for net product sales of USD 173 million to USD 183 million and adjusted EBITDA of USD 10 million to USD 20 million after uncertainty around the CINVANTI patent situation and broader strategic alternatives.

Analysts keep a Hold view

MarketBeat reported on September 25, 2026, that five analysts carried a consensus Hold rating, comprising one Buy, three Hold and one Sell recommendation. The average 12-month price target was USD 2.00, with the same source reporting USD 0.34 as the reference price in its market discussion.

For investors, the central tension is visible in the numbers: quarterly sales edged above the prior-year level, but the loss widened and guidance was withdrawn. Heron develops and commercializes medicines for acute care and oncology, including ZYNRELEF and APONVIE, while the license agreement offers a route to expand that portfolio.

Heron Therapeutics stock stays below USD 1

Heron Therapeutics stock was trading at USD 0.34 on Nasdaq on October 6, 2026. The 52-week range was USD 0.26 to USD 1.58, and volume reached 832,260 shares on that date.